PuraCath Medical Presents Data at 2014 Annual Meeting of the American Society of Nephrology

puracath • Nov 14, 2014

Company presents study on the effectiveness of UV light to purify peritoneal dialysis catheter connections

PuraCath Medical, an emerging company in the development of technologies to reduce infections in dialysis patients, announced today that it presented scientific data during Kidney Week 2014 demonstrating the ability to reduce bacterial growth in a simulated peritoneal dialysis delivery system when combining ultraviolet (UV) light with a UV transmissible connection system. The study represents early results with an initial version of the technology PuraCath Medical is developing which will be designed to reduce connectology-related bacterial contamination for PD patients.

“Infectious complications remain a major risk for patients receiving PD and represent a leading cause of technique failure and transition to hemodialysis,” stated study co-author and nephrologist Glenn Chertow, M.D. “Approaches that can reduce bacterial contamination during peritoneal exchanges should reduce the risk of peritonitis and allow patients to remain on home-based therapy. In order to allow patients to choose PD and to remain on PD long-term, we need to reduce peritonitis risk. I believe the approach PuraCath Medical is taking will help us get there.”

“We are encouraged by the study results we presented during the ASN meeting which support our planned development of a novel UV light-based PD purification system,” said Julia Rasooly, PuraCath Medical’s CEO. “Since PuraCath Medical recognizes the value and the lifestyle convenience peritoneal dialysis therapy offers to patients, we are developing a PD disinfection system that enhances their quality of life and provides an easy-to-use, patient friendly option to reducing bacterial and fungal contamination during PD exchanges.”

WHAT IS PERITONEAL DIALYSIS?
Peritoneal dialysis is a home-based dialysis therapy that offers patients a more flexible and physiologically smoother dialysis option. Unlike hemodialysis, peritoneal dialysis uses a patient’s peritoneal membrane to remove toxins and excess fluid from a patient. Peritoneal dialysis therapy permits patients to have a more regular diet and more flexible treatment times, improving their quality of life. Currently there are nearly 40,000 peritoneal dialysis patients in the U.S. with the number of patients on this therapy increasing over the past several years. The most common complications from peritoneal dialysis include infection around the catheter site or infection of the lining of the abdominal wall (peritonitis).

ABOUT PURACATH MEDICAL
PuraCath Medical is a company based in Mountain View, CA and is dedicated to improving the quality of life for the dialysis patient by reducing infections related to peritoneal dialysis (PD) and saving time through improved, simplified connection of PD catheters. The Company utilizes technology that was spun out of Stanford University and is developing a novel easy-to-use technology designed to reduce infections and improve outcomes for patients on PD therapy. For more information on PuraCath Medical, please visit http://www.puracath.com.

CONTACT
Julia Rasooly, M.S.
President and Chief Executive Officer
+1.650.559.0388

PuraCath Medical Receives 510(k) Clearance for its Needleless Connector for Vascular Access
By puracath 03 Aug, 2021
Device is intended for use primarily by ICU nurses during infusions in patients in a critical care setting. PuraCath Medical™, a venture-backed startup company focusing on the development of technologies to reduce infections in patients with intravascular catheters, announced today that it has received 510(k) clearance for its FireFly™ Needleless Connector from the U.S. Food […]
Why We Aren’t Using UV to Disinfect Everything—Yet
By puracath 16 Jun, 2020
Negative perception and costs pose obstacles to a promising technology As the coronavirus pandemic continues, a technology that has existed for over 100 years is getting renewed attention as a promising disinfection tool. Ultraviolet germicidal radiation, which uses short-wavelength UV rays to kill bacteria and viruses, is already used to disinfect the air, water, and […]
PuraCath UV Device Displays a 99.9999% Disinfection of COVID-19 Virus in 1 Second
By puracath 27 Apr, 2020
PuraCath has been partnered and working with a top tier BSL-3 National Laboratory, which has a premiere high containment infectious disease facilities to test its Firefly UV device for the ICU and hospitals with 2019-nCoV (the COVID-19 virus). The preliminary results show that PuraCath’s device has achieved 99.9999% disinfection with SARS-CoV-2 (the virus that is […]
PuraCath FireflyTM Can Kill Deadly Microorganisms with UV Light, Like SARS CoV-2
By puracath 19 Mar, 2020
President Trump has officially declared a national emergency. A novel coronavirus has been identified in Wuhan City, China and has spread worldwide. It has been named SARS CoV-2 (causing disease COVID-19) by WHO. SARS CoV-2 has officially become a global pandemic by WHO. There have already been over 170,000 confirmed cases to date with an […]
By puracath 19 Jun, 2019
JUNE 18, 2019 PuraCath Medical, a venture-backed medical device company based in Silicon Valley, announced today that it has achieved 99.99% disinfection on its vascular access Firefly disinfection technology system with Candida auris (‘superbug’), Staphylococcus aureus, and Candida albicans. “Achieving greater than 4 log disinfection in these virulent microbes with only one second of UV […]
By puracath 07 Mar, 2017
San Francisco, California (March 7, 2017) – PuraCath Medical has published the result of its recent research on its ultraviolet (UV) light-based peritoneal dialysis catheter connection system in Peritoneal Dialysis International (PDI), the official Journal of the International Society for Peritoneal Dialysis. PDI is a major source of knowledge in the field of peritoneal dialysis and aims […]
PuraCath Medical to Present Data on FireFly™ Peritoneal Dialysis Connector Disinfecting System durin
By Larry Yost 12 May, 2016
San Francisco, California (May 12, 2016) – Data being presented will support planned introduction of PuraCath Medical’s technology in the European Union. PuraCath Medical, an emerging company in the development of technologies to reduce infections in patients with intravascular and peritoneal catheters, announced today that it will present data on its next generation version of the FireFly™ […]
PuraCath Medical Presents Data at National Kidney Foundation 2016 Spring Clinical Meetings
By Larry Yost 28 Apr, 2016
Boston, Massachusetts (April 28, 2016) – PuraCath Medical, an emerging company in the development of technologies to reduce infections in patients with intravascular and peritoneal catheters, announced today that it presented data on its next generation version of the FireFly™ Peritoneal Dialysis (PD) Connector Disinfecting System during the National Kidney Foundation’s 2016 Spring Clinical Meetings held […]
PuraCath Medical Presents New Research Data during 36th Annual Dialysis Conference
By Larry Yost 29 Feb, 2016
Company presents study on the effectiveness of next-generation version of the FireFly™ Peritoneal Dialysis Connector Disinfecting System Seattle, Washington (February 29, 2016) – PuraCath Medical, an emerging company in the development of technologies to reduce infections in patients with intravascular and peritoneal catheters, announced today that it presented data on its next generation version of […]
PuraCath Medical Receives 510(k) Clearance for the FireFly™ Peritoneal Dialysis Connector Disinfecti
By puracath 26 Jan, 2016
PuraCath Medical, an emerging company in the development of technologies to reduce infections in patients with intravascular and peritoneal catheters, announced today that it has received 510(k) clearance for its FireFly™ Peritoneal Dialysis Connector Disinfecting System from the U.S. Food and Drug Administration (FDA). This regulatory determination by the FDA gives PuraCath clearance to market […]
More Posts
Share by: